Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Membranous Nephropathy: Core Curriculum 2021.

Loulwa Alsharhan1, Laurence H Beck2

  • 1Section of Nephrology, Department of Medicine, Boston Medical Center, Boston, MA.

American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation
|January 25, 2021
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The podocyte slit-diaphragm: target of anti-nephrin antibodies.

Current opinion in nephrology and hypertension·2026
Same author

Circulating Testican-2 and MGT5A are Markers of Membranous Nephropathy.

Kidney international reports·2026
Same author

Associations of Podocyte-Derived Protein Biomarkers With Foot Process Effacement and Kidney Histopathologic Lesions in Individuals With Glomerular Disease.

Kidney medicine·2025
Same author

Nucleophosmin Promotes Regulated Cell Death in Podocyte Injury.

Kidney360·2025
Same author

The Associations of Foot Process Effacement with Kidney Histopathologic Lesions and Disease Progression.

Kidney360·2025
Same author

The podocyte gets a pedicure: tiny nail clippers for podocyte foot processes.

Kidney international·2025

Membranous nephropathy management has advanced with target antigen identification and autoantibody monitoring. Rituximab is now a leading treatment for primary membranous nephropathy, shifting from traditional immunosuppression.

Area of Science:

  • Nephrology
  • Immunology
  • Internal Medicine

Background:

  • Membranous nephropathy is a leading cause of nephrotic syndrome, predominantly in adults.
  • Understanding of its pathogenesis has significantly evolved.
  • Advances include target antigen identification and autoantibody monitoring.

Purpose of the Study:

  • To review the evolving understanding and management of membranous nephropathy.
  • To highlight key target antigens and their diagnostic significance.
  • To discuss modern treatment strategies, including novel immunotherapies.

Main Methods:

  • Review of current literature and clinical trial data.
  • Discussion of diagnostic criteria and immunologic markers.
  • Analysis of treatment outcomes for various immunosuppressive regimens.
Keywords:
M-type phospholipase A(2) receptor (PLA(2)R)Membranous nephropathy (MN)alloimmune MNautoantibodyde novo MNexostosin 1 and 2 (EXT1/2)neural epidermal growth factor-like 1 (NELL-1)pathophysiologyprimary MNrecurrent MNreviewsecondary MNsemaphorin-3B (Sema3B)thrombospondin type 1 domain-containing 7A (THSD7A)treatment

Related Experiment Videos

Main Results:

  • Identification of phospholipase A2 receptor (PLA2R), THSD7A, and others as key antigens.
  • Circulating autoantibodies serve as crucial biomarkers for diagnosis and monitoring.
  • Rituximab demonstrates efficacy, positioning it as a frontline therapy for primary membranous nephropathy.

Conclusions:

  • Precise molecular diagnoses are now possible through antigen identification.
  • Autoantibody monitoring aids in disease management and treatment decisions.
  • Modern management integrates supportive care with targeted immunosuppression, notably rituximab.